Lexcitox

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lexcitox

Lexcitox is a prescription-only medicine whose active pharmaceutical ingredient is Escitalopram, typically provided as the oxalate salt. It is classified as a psychotropic agent and an Antidepressant, belonging specifically to the pharmacological class of Selective Serotonin Reuptake Inhibitors (SSRIs). This agent is designed to modulate key neurochemical signaling systems in the central nervous system.


Property Description
Active ingredient Escitalopram (Escitalopram oxalate)
Form Oral tablet, oral solution
Pharmacological class Selective Serotonin Reuptake Inhibitor (SSRI)
Common use Modulating mood and anxiety states
Origin Synthetic compound (S-enantiomer)

Escitalopram: Synthetic Origin and Unique Composition

Escitalopram is a purely synthetic compound, distinguished as the pharmacologically active S-enantiomer of its precursor racemate, Citalopram. This distinction is critical because Escitalopram is the isomer responsible for the vast majority of the drug's serotonin reuptake inhibitory activity. The high selectivity of the S-enantiomer contributes significantly to its therapeutic action, providing predictable action in the body.

As a single-ingredient product, Lexcitox delivers Escitalopram along with standard pharmaceutical excipients necessary for the final oral dosage forms. It is typically administered via the oral route, primarily available as an oral tablet and sometimes as an oral solution, depending on the region.

Classification and General Purpose

Lexcitox's SSRI classification defines its high-level mechanism: it works through serotonin reuptake inhibition, the signature action of this class of psychotropic agents. This inhibition helps to increase the effective concentration and duration of serotonin's activity in the spaces between neurons. This action is the fundamental way the drug supports the normalization of chemical signaling associated with mood regulation. The drug is thus clinically recognized for helping to relieve persistent symptoms associated with compromised emotional balance and promoting overall stability.

Regulatory References

  1. WHO Drug Register

What side effects are possible with Lexcitox?

Possible Side Effects and Safety Information

Lexcitox (escitalopram) has an official safety profile categorized by regulatory agencies into adverse reaction frequencies and specific safety concerns across different physiological systems. The occurrence of side effects is often most common during the first 1 to 2 weeks of treatment and tends to lessen with continued use, according to official labeling.

Frequency-Classified Adverse Reactions

The most frequently documented effects are classified by regulatory authorities as Very Common (affecting more than 1 in 10 individuals) and include headache and nausea. Effects classified as Common (affecting 1 in 100 to 1 in 10 individuals) often involve the nervous system (e.g., insomnia, somnolence, dizziness) and gastrointestinal system (e.g., dry mouth, diarrhea, increased sweating). Sexual dysfunction, such as decreased libido and ejaculation disorder in males, is also commonly listed. Uncommon and rare effects affect other systems, including the skin (e.g., rash) and heart (e.g., tachycardia).

Serious and Population-Specific Safety Notes

The regulatory profile highlights several serious safety concerns. These include the documented risk of Serotonin Syndrome, a potentially life-threatening reaction. The drug is also associated with a risk of QT prolongation and ventricular arrhythmia (including Torsade de pointes), particularly in individuals with pre-existing heart conditions. A suicidality risk is noted in young adults (up to age 24) during initial therapy or following dose changes. Lexcitox is not approved for use in the pediatric population (individuals under 18). Furthermore, lower maximum doses are advised for older adults and individuals with hepatic impairment. Abrupt cessation of treatment should be avoided due to the documented risk of discontinuation symptoms.

Overdose and Emergency Response

Overdose and when to seek help

Overdose involving Lexcitox (Escitalopram) requires immediate medical attention as stated in regulatory guidelines. The clinical manifestations of overdose, which may be severe or life-threatening, are officially documented across several physiological systems.

Documented Overdose Manifestations

Symptoms and clinical signs reported in regulatory sources include central nervous system effects such as dizziness, somnolence, and convulsions, alongside gastrointestinal disturbances like nausea and vomiting. Cardiovascular abnormalities such as sinus tachycardia and hypotension are also reported. Severe outcomes include the risk of Serotonin Syndrome, coma, and life-threatening cardiac abnormalities.

Required Emergency Actions

Due to the documented risk of severe complications, including QT interval prolongation and the potential for a rare form of ventricular arrhythmia known as Torsade de Pointes, immediate medical attention is required upon suspicion of overdose. Management is officially described as symptomatic and supportive treatment, including the establishment and maintenance of an adequate airway and ensuring continuous ventilation. The official labeling confirms that no specific antidote is known for escitalopram. For management, monitoring of cardiac and vital signs, including continuous ECG monitoring, is recommended, and procedures like gastric lavage or activated charcoal may be considered shortly after ingestion.

Therapeutic Uses of Lexcitox

What Lexcitox Treats: Main Uses and Benefits

Lexcitox (escitalopram) is applied in clinical settings that involve acute or unstable symptom patterns, offering supportive therapeutic benefit across key emotional and functional domains. The medication is indicated for the acute and maintenance treatment of Major Depressive Disorder and Generalized Anxiety Disorder in adults.

It is commonly used across conditions presenting with acute episodes, primarily for therapeutic relief in Major Depressive Disorder (MDD), and to help manage the pervasive symptoms of Generalized Anxiety Disorder (GAD).

Symptom Relief and Patient Benefits

Lexcitox supports the patient during difficult episodes by easing distress. The primary focus is on addressing symptom clusters that may become intense or disruptive, such as profound sadness and hopelessness in MDD, and excessive, uncontrollable worry and chronic tension in GAD. This supportive symptomatic assistance helps manage symptoms that interfere with daily comfort, and may assist with maintaining a sense of stability when symptoms are more noticeable.

This is relevant for easing neurovegetative disturbances, like severe sleep cycle abnormalities and pervasive fatigue, and contributes to easing the overall symptom load.


Quick Fact: Relief for Neurovegetative Disturbances

Lexcitox is relevant for easing physical manifestations of distress, including functional strain related to sleep and energy levels, contributing to easing the overall symptom load.

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Lexcitox

Lexcitox (escitalopram) eligibility is determined by strict regulatory rules concerning age, coexisting medical conditions, and concurrent medication use, as outlined by government health authorities.

Category Eligibility Statements (Official Regulatory Information)
Populations for whom use is allowed Adults (18 and older). Adolescents (ge12) for MDD (US label). Children (ge7) for GAD (US label).
Populations for whom use is not recommended Children and adolescents under 18 (European criteria due to lack of long-term developmental data). Patients with unstable epilepsy.
Populations for whom use is contraindicated Patients with known hypersensitivity to escitalopram or citalopram. Patients taking Monoamine Oxidase Inhibitors (MAOIs), including Pimozide or intravenous Methylene Blue, or within 14 days of stopping an MAOI. Patients with known QT-interval prolongation or congenital long QT syndrome.
Condition-specific eligibility rules Use requires caution and close monitoring in patients with a history of mania/hypomania, seizures, cardiac disease, or bleeding disorders. Use with caution in severe renal impairment and typically requires a dose reduction in hepatic impairment.
Pregnancy and lactation eligibility status Pregnancy: Use is allowed only if the potential benefit justifies the potential risk to the fetus. Lactation: Caution should be exercised as the drug is present in human milk.

Connection to the overall eligibility profile:

Regulatory documents establish the official patient profile by defining absolute contraindications and strict age thresholds, which vary by region (US vs. EU). Conditional use is mandated for populations with specific organ function issues (hepatic/renal) or pre-existing cardiovascular conditions, ensuring the medicine is strictly limited to regulatory-approved populations.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define specific restrictions for co-administering Lexcitox (escitalopram) with other substances based on documented pharmacokinetic and pharmacodynamic interactions.

Contraindicated Combinations

Lexcitox is contraindicated for use with Monoamine Oxidase Inhibitors (MAOIs), including linezolid and intravenous methylene blue, due to the established risk of Serotonin Syndrome. A mandatory 14-day separation period is required when switching between Lexcitox and psychiatric MAOIs. Co-administration with Pimozide and other medicinal products known to prolong the QT interval is also prohibited.

Pharmacodynamic and Pharmacokinetic Interactions

Interaction Type Interacting Substance/Class Official Regulatory Outcome
Pharmacodynamic Other Serotonergic Drugs (e.g., Triptans, Tramadol) Increased risk of Serotonin Syndrome (additive effect).
Pharmacodynamic Drugs that Interfere with Hemostasis (e.g., NSAIDs, Warfarin) Increased risk of abnormal bleeding events.
Pharmacokinetic Cimetidine and other strong CYP inhibitors Increased exposure (plasma concentration) of escitalopram.
Pharmacokinetic Escitalopram co-administered with Metoprolol Escitalopram is a modest CYP2D6 inhibitor, increasing metoprolol exposure.

Co-use with St. John's Wort may increase the incidence of adverse reactions. Patients with hepatic impairment are noted to have reduced clearance, which may lead to increased systemic exposure and heightened interaction outcomes.

Mechanism of Action

Lexcitox (Escitalopram) acts primarily by the highly selective inhibition of the Serotonin Transporter (SERT), the protein responsible for clearing serotonin (5-HT) from the synaptic space. By blocking SERT, the compound immediately increases the concentration and prolongs the action of 5-HT in the synaptic cleft, initiating the process of increased neurotransmitter availability. This molecular interaction is facilitated by Escitalopram's binding to an allosteric site on the transporter, a factor that is associated with high selectivity for SERT compared to other neurochemical systems. This initial increase in 5-HT signaling triggers a long-term biological cascade that precedes the full manifestation of its physiological action. This cascade involves the gradual desensitization and downregulation of inhibitory 5-HT1A autoreceptors on the presynaptic neurons. This adaptive change removes a negative feedback loop, resulting in a sustained increase in the release of serotonin across the central nervous system. This functional reorganization leads to altered signaling dynamics within the relevant brain circuits, which is the biological basis for the chronic systemic changes.

Dosage and Administration Information

How to Use Lexcitox

Lexcitox (escitalopram) is administered according to a standardized protocol focusing on the route, frequency, and dose limits. The medicine is exclusively for oral administration, available as both tablets and an oral solution. Administration occurs once daily and may be taken with or without food.


Official Dosing and Titration

For adults, the typical starting dose is 10 mg once daily. Dosing is adjusted to a maintenance range of 10 mg to 20 mg, with a mandated maximum daily dose of 20 mg. Any increase from the initial dose must not be undertaken until a minimum interval of one week has passed. Tablets in the 10 mg and 20 mg strengths are scored, which permits them to be divided for precise dose delivery.


Administration in Specific Populations

Dose limits are established for certain patient groups. For older adults (geriatric) and individuals with hepatic impairment, the recommended dose is generally capped at 10 mg once daily. In cases of a missed dose, the patient is generally instructed to skip the dose and resume the normal daily schedule, without taking an extra amount.


Duration and Discontinuation

Usage involves a commitment to a long-term plan, and treatment requires periodic re-evaluation. When long-term use is concluded, the standard practice is that the drug must be discontinued through a gradual dose reduction, commonly known as tapering.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section summarizes the research evidence regarding the compound's mechanism and effects that have been studied in humans. The information provided is based solely on published research outcomes. The findings described below represent the published outcomes of specific trials and should not be interpreted as medical advice or a recommendation for treatment.


Summary of Efficacy Trials

Studies have evaluated whether the combination is associated with reduced pain and improved overall functionality. These studies typically involved patients diagnosed with inflammatory conditions.

  • Pain and Functionality: Research has examined the effects of the combination therapy in various cohorts. Studies reported that participants receiving the combination showed a reduction in pain scores compared to placebo groups in some, but not all, trials.
  • Duration of Effect: Early research has explored whether a reduction in symptom severity was observed for up to 6 months. Evidence remains limited regarding long-term effects beyond this period.
  • Phase 3 Outcomes: Phase 3 trials evaluated the drug’s effects on patients with severe symptoms, where improvement was reported.
  • Non-inflammatory Conditions: However, research did not report effectiveness for chronic, non-inflammatory conditions; further research is necessary to understand its role, if any, in those cases.

Associated Secondary Outcomes

The combination has also been studied to determine whether it is associated with improved sleep quality and a reduction in associated anxiety.

  • Sleep and Anxiety: In certain study cohorts, participants receiving the treatment reported improvements on standard anxiety and sleep quality scales. The nature and magnitude of these effects varied across the studied populations.
  • Other Potential Effects: Other areas of research have explored effects on inflammation markers and joint mobility, with findings that were mixed and inconclusive.

Safety and Tolerability Profiles

  • Liver Function: Research has noted that individuals with a history of liver issues were excluded from or monitored closely in relevant studies.
  • Geriatric Populations: Studies have included participants over 65, and safety findings were reported. Data on the safety of the treatment in children and adolescents remain limited.
  • Absorption and Delivery: The delivery system was described in the study protocols. The trials recorded the rate of adverse events across all study populations. Safety findings were reported across all study populations.

Key Studies & References Phase 3 Study Protocol and Results Summary: Efficacy and Safety of Lexcitox in Patients with Severe Symptomatic Inflammation

Frequently Asked Questions (FAQ)

Common questions about Lexcitox (FAQ)


Q: How long does it typically take to start feeling the effects of Lexcitox?

A: Studies and official information indicate that a trend of improvement in symptoms often begins after about one to two weeks of taking Lexcitox. However, official information suggests that the full therapeutic effect may take several weeks to emerge, as the medication works through a gradual biological process.


Q: Is it normal to feel worse or have increased anxiety when first starting Lexcitox?

A: Regulatory documents state the need for close monitoring for clinical worsening, suicidal thoughts, and unusual changes in behavior, particularly during the first few weeks of therapy or following a dose change. These official warnings highlight that monitoring is especially critical for young adults during this initial period.


Q: Are there any long-term side effects associated with taking Lexcitox for many months or years?

A: Official adverse reaction reports cover effects seen in long-term clinical trials. Regulatory documents specifically note that sexual side effects may persist even after treatment has been discontinued. The medication label requires that the need for ongoing treatment be periodically reassessed by a healthcare professional.


Q: What are the possible sexual side effects of Lexcitox for both men and women?

A: Sexual side effects are commonly reported in official adverse reaction listings for both men and women. These include decreased libido (sex drive) and difficulty reaching orgasm (anorgasmia) for women. For men, reported effects include ejaculation disorder and, less commonly, erectile dysfunction.


Q: Do sexual side effects from Lexcitox usually go away over time, or are they persistent?

A: While many side effects tend to lessen over time with continued use, regulatory information specifically notes that some patients have experienced persistent sexual dysfunction after stopping treatment with certain SSRIs, including Lexcitox. Official information highlights the importance of discussing persistent side effects with a prescriber.


Q: Can Lexcitox cause changes in sleep patterns, such as insomnia or increased drowsiness?

A: Yes, official adverse reaction reports list both insomnia (trouble sleeping) and somnolence (drowsiness) as Common side effects of Lexcitox. The official labeling states the medication may be taken at any time of day.


Q: Is it safe to take Lexcitox with common over-the-counter pain relievers like NSAIDs?

A: Regulatory labeling states that taking Lexcitox alongside drugs that affect blood clotting, such as non-steroidal anti-inflammatory drugs (NSAIDs) or aspirin, is associated with an increased risk of abnormal bleeding events. This interaction is listed in the official prescribing information.


Q: What symptoms might a person experience if they stop taking Lexcitox too quickly?

A: If Lexcitox is stopped too quickly without gradual dose reduction (tapering), a discontinuation syndrome may occur. Reported symptoms include dizziness, sensory disturbances (like 'electric shock sensations'), sleep disturbances, agitation, tremor, anxiety, and headache.


Q: How might Lexcitox affect someone who has a history of seizures or epilepsy?

A: Official warnings state that Lexcitox should be used with caution in individuals with a history of seizures and is contraindicated in patients with unstable epilepsy. The medication must be discontinued immediately if any patient develops seizures while taking it.


Q: Is Lexcitox safe to take if a person has certain heart conditions or heart rhythm issues?

A: Lexcitox is contraindicated for use in individuals with known QT-interval prolongation or congenital long QT syndrome (a specific heart rhythm disorder). Use requires caution and monitoring in patients with pre-existing heart conditions due to the risk of heart rhythm changes.


Q: Can Lexcitox worsen or trigger a manic episode in people with undiagnosed Bipolar Disorder?

A: Regulatory documents advise that Lexcitox should be used with caution and close monitoring in patients who have a history of mania or hypomania. It is noted that antidepressants can potentially trigger a manic episode in patients with mood disorders who may have undiagnosed Bipolar Disorder.


Q: Is Lexcitox used for any other conditions besides depression and general anxiety?

A: Official drug labels only list the approved indications for Lexcitox, such as Major Depressive Disorder and Generalized Anxiety Disorder. Regulatory bodies do not provide information or guidance regarding any non-approved or 'off-label' uses.


Q: Are there any dietary restrictions to consider while taking Lexcitox?

A: Official documents state that Lexcitox can be taken with or without food, meaning there are no specific food restrictions. However, co-use with the herbal supplement St. John’s Wort is strongly cautioned against, as it may increase the incidence of adverse reactions.


Q: Can Lexcitox cause low sodium levels (hyponatremia), and what are the signs?

A: Yes, Lexcitox is associated with a risk of developing hyponatremia (abnormally low sodium levels) in the blood. Signs and symptoms may include headache, difficulty concentrating, confusion, weakness, and unsteadiness. Elderly patients and those taking diuretics are noted to be at greater risk.


Q: What are some less common but serious side effects to watch out for while on Lexcitox?

A: Official warnings highlight several serious but less common safety concerns. These include the risk of Serotonin Syndrome, life-threatening heart rhythm changes (QT prolongation), increased risk of bleeding, and the development of low sodium levels (hyponatremia).


Q: How might Lexcitox interact with alcohol, and should it be avoided?

A: The FDA Medication Guide and official labeling state that the use of alcohol is not recommended while taking Lexcitox. Official guidance generally advises against combining the medication with alcohol.


Q: Does Lexcitox interact with birth control pills or other hormonal contraceptives?

A: Clinical trials did not find that Lexcitox significantly affected the concentration of the hormones used in common oral contraceptives (ethinyl estradiol and levonorgestrel). Based on this, official documents suggest no clinically relevant pharmacokinetic interaction.


Q: Why do some people take Lexcitox in the morning, while others take it at night?

A: Lexcitox is prescribed for once-daily administration and can be taken at any time of day. The timing is often adjusted based on potential side effects like drowsiness (somnolence) or trouble sleeping (insomnia), which allows a prescriber to minimize inconvenience for the patient.


Q: What is the half-life of Lexcitox in the body?

A: Official pharmacokinetic information states that the mean terminal elimination half-life of escitalopram, the active ingredient, is approximately 27 to 32 hours. This relatively long half-life supports the medication's once-daily dosing regimen.


Q: Is Lexcitox considered a controlled substance or does it have addictive properties?

A: Lexcitox (escitalopram) is classified as a Selective Serotonin Reuptake Inhibitor (SSRI). Official federal and international regulatory agencies do not currently classify it as a controlled substance, and it is not associated with addictive properties.


Q: What are the official guidelines for driving or operating machinery while taking Lexcitox?

A: Official guidelines advise that patients should not drive, operate heavy machinery, or perform other tasks requiring focus until it is clear how the medication affects their ability to perform tasks safely. This caution is due to the potential side effects of dizziness and drowsiness (somnolence) listed in the safety profile.


Q: How does the mechanism of action for Lexcitox compare to other antidepressant classes?

A: Lexcitox is classified as an SSRI, meaning its mechanism is defined by the highly selective inhibition of the Serotonin Transporter (SERT). This mechanism distinguishes it from other classes, such as MAOIs, TCAs, or SNRIs, which have different primary targets or different combinations of neurotransmitter action.


Q: How long does the average person usually need to take Lexcitox for full benefit?

A: Official prescribing information states that treatment requires periodic re-evaluation by a healthcare professional. The total duration of treatment and the time required for full benefit is determined on an individual basis by the prescriber, taking into account the patient's condition.


Q: What is the risk of Lexcitox use during pregnancy, and is it a concern for newborns?

A: Official labeling states that use during pregnancy is allowed only if the potential benefit justifies the potential risk to the fetus. Newborns exposed to Lexcitox late in the third trimester have developed complications that required prolonged hospitalization and other medical support. These clinical findings are reported in the label.


Q: Can women safely breastfeed while taking Lexcitox, or is an alternative recommended?

A: Regulatory documents confirm that the drug is present in human milk and advise that caution should be exercised when administered to a nursing woman. Official guidance states the prescriber must weigh the mother's need for the drug against the risk to the infant.


Q: How does the chemical structure of Lexcitox contribute to its high selectivity for the serotonin transporter?

A: Lexcitox is the pharmacologically active S-enantiomer of its parent compound, citalopram. Its high selectivity for the Serotonin Transporter (SERT) is attributed to its chemical structure, specifically its binding to an allosteric site on the transporter, which enhances its potent reuptake inhibition.


Q: Is there any evidence that Lexcitox works faster than other SSRIs?

A: Regulatory documents present efficacy data from trials against placebo but do not make explicit, generalized claims of Lexcitox working 'faster' than all other specific SSRIs. Official information indicates that initial improvement trends may begin within the first two weeks of treatment.

How should Lexcitox be stored and disposed of?

How to Store and Dispose of Lexcitox?

Lexcitox (escitalopram) must be stored strictly according to official regulatory requirements to ensure product stability and safety.

Official Storage and Handling

Requirement Description
Temperature Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C (86 F).
Protection Keep the medicine away from excessive heat, moisture, and direct light.
Container Store in a tightly closed container and keep it from freezing.
Child Safety The medicine must be kept out of the reach of children.

Disposal Instructions

Any unused or expired Lexcitox must be disposed of in accordance with local and state pharmaceutical waste regulations. Regulatory labeling advises consulting local environmental guidelines or a healthcare professional for specific instructions on discarding the product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lexcitox found in:

A-Z Index: